▶ 調査レポート

世界の抗レトロウイルス医薬品市場 2021:企業別、地域別、種類・用途別

• 英文タイトル:Global Anti-Retroviral Drugs Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の抗レトロウイルス医薬品市場 2021:企業別、地域別、種類・用途別 / Global Anti-Retroviral Drugs Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 / GIR-107A14393資料のイメージです。• レポートコード:GIR-107A14393
• 出版社/出版日:GlobalInfoResearch / 2021年7月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、103ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥522,000 (USD3,480)▷ お問い合わせ
  Multi User¥783,000 (USD5,220)▷ お問い合わせ
  Corporate User¥1,044,000 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料では、抗レトロウイルス医薬品のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。抗レトロウイルス医薬品の種類別市場規模(プロテアーゼ阻害剤、非ヌクレオシド逆転写酵素阻害剤、インテグラーゼ阻害剤、ヌクレオシド類似体およびヌクレオシド逆転写酵素阻害剤)、用途別市場規模(肝炎、HIV / AIDS、ヘルペス、インフルエンザ、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・抗レトロウイルス医薬品の市場概要
・企業情報(企業概要、製品概要、販売量、価格、売上):Cardionet、GE Healthcare、Abbott、AstraZeneca、Bristol-Myers-Squibb、Gilead、Cardiac Science Corp.、Cardiocom、Biotelemetry、GlaxoSmithKline、Roche
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:プロテアーゼ阻害剤、非ヌクレオシド逆転写酵素阻害剤、インテグラーゼ阻害剤、ヌクレオシド類似体およびヌクレオシド逆転写酵素阻害剤
・用途別分析2016年-2026年:肝炎、HIV / AIDS、ヘルペス、インフルエンザ、その他
・抗レトロウイルス医薬品の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・抗レトロウイルス医薬品のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・抗レトロウイルス医薬品のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・抗レトロウイルス医薬品の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・抗レトロウイルス医薬品の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Anti-Retroviral Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Anti-Retroviral Drugs size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Anti-Retroviral Drugs market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Anti-Retroviral Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Protease Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Integrase Inhibitors
Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors

Market segment by Application can be divided into
Hepatitis
HIV/AIDS
Herpes
Influenza
Others

The key market players for global Anti-Retroviral Drugs market are listed below:
Cardionet
GE Healthcare
Abbott
AstraZeneca
Bristol-Myers-Squibb
Gilead
Cardiac Science Corp.
Cardiocom
Biotelemetry
GlaxoSmithKline
Roche

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Anti-Retroviral Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Anti-Retroviral Drugs, with price, sales, revenue and global market share of Anti-Retroviral Drugs from 2019 to 2021.
Chapter 3, the Anti-Retroviral Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anti-Retroviral Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Anti-Retroviral Drugs market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Anti-Retroviral Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Anti-Retroviral Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Anti-Retroviral Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Protease Inhibitors
1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors
1.2.4 Integrase Inhibitors
1.2.5 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
1.3 Market Analysis by Application
1.3.1 Overview: Global Anti-Retroviral Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hepatitis
1.3.3 HIV/AIDS
1.3.4 Herpes
1.3.5 Influenza
1.3.6 Others
1.4 Global Anti-Retroviral Drugs Market Size & Forecast
1.4.1 Global Anti-Retroviral Drugs Sales in Value (2016-2026))
1.4.2 Global Anti-Retroviral Drugs Sales in Volume (2016-2026)
1.4.3 Global Anti-Retroviral Drugs Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Anti-Retroviral Drugs Production Capacity Analysis
1.5.1 Global Anti-Retroviral Drugs Total Production Capacity (2016-2026)
1.5.2 Global Anti-Retroviral Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Anti-Retroviral Drugs Market Drivers
1.6.2 Anti-Retroviral Drugs Market Restraints
1.6.3 Anti-Retroviral Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Cardionet
2.1.1 Cardionet Details
2.1.2 Cardionet Major Business
2.1.3 Cardionet Anti-Retroviral Drugs Product and Services
2.1.4 Cardionet Anti-Retroviral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 GE Healthcare
2.2.1 GE Healthcare Details
2.2.2 GE Healthcare Major Business
2.2.3 GE Healthcare Anti-Retroviral Drugs Product and Services
2.2.4 GE Healthcare Anti-Retroviral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Abbott
2.3.1 Abbott Details
2.3.2 Abbott Major Business
2.3.3 Abbott Anti-Retroviral Drugs Product and Services
2.3.4 Abbott Anti-Retroviral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Anti-Retroviral Drugs Product and Services
2.4.4 AstraZeneca Anti-Retroviral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Bristol-Myers-Squibb
2.5.1 Bristol-Myers-Squibb Details
2.5.2 Bristol-Myers-Squibb Major Business
2.5.3 Bristol-Myers-Squibb Anti-Retroviral Drugs Product and Services
2.5.4 Bristol-Myers-Squibb Anti-Retroviral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Gilead
2.6.1 Gilead Details
2.6.2 Gilead Major Business
2.6.3 Gilead Anti-Retroviral Drugs Product and Services
2.6.4 Gilead Anti-Retroviral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Cardiac Science Corp.
2.7.1 Cardiac Science Corp. Details
2.7.2 Cardiac Science Corp. Major Business
2.7.3 Cardiac Science Corp. Anti-Retroviral Drugs Product and Services
2.7.4 Cardiac Science Corp. Anti-Retroviral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Cardiocom
2.8.1 Cardiocom Details
2.8.2 Cardiocom Major Business
2.8.3 Cardiocom Anti-Retroviral Drugs Product and Services
2.8.4 Cardiocom Anti-Retroviral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Biotelemetry
2.9.1 Biotelemetry Details
2.9.2 Biotelemetry Major Business
2.9.3 Biotelemetry Anti-Retroviral Drugs Product and Services
2.9.4 Biotelemetry Anti-Retroviral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 GlaxoSmithKline
2.10.1 GlaxoSmithKline Details
2.10.2 GlaxoSmithKline Major Business
2.10.3 GlaxoSmithKline Anti-Retroviral Drugs Product and Services
2.10.4 GlaxoSmithKline Anti-Retroviral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 Roche
2.11.1 Roche Details
2.11.2 Roche Major Business
2.11.3 Roche Anti-Retroviral Drugs Product and Services
2.11.4 Roche Anti-Retroviral Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Anti-Retroviral Drugs Sales by Manufacturer
3.1 Global Anti-Retroviral Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Anti-Retroviral Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Anti-Retroviral Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Anti-Retroviral Drugs Manufacturer Market Share
3.4.2 Top 6 Anti-Retroviral Drugs Manufacturer Market Share
3.5 Global Anti-Retroviral Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Anti-Retroviral Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Anti-Retroviral Drugs Market Size by Region
4.1.1 Global Anti-Retroviral Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Anti-Retroviral Drugs Revenue by Region (2016-2026)
4.2 North America Anti-Retroviral Drugs Revenue (2016-2026)
4.3 Europe Anti-Retroviral Drugs Revenue (2016-2026)
4.4 Asia-Pacific Anti-Retroviral Drugs Revenue (2016-2026)
4.5 South America Anti-Retroviral Drugs Revenue (2016-2026)
4.6 Middle East and Africa Anti-Retroviral Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Anti-Retroviral Drugs Sales in Volume by Type (2016-2026)
5.2 Global Anti-Retroviral Drugs Revenue by Type (2016-2026)
5.3 Global Anti-Retroviral Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Anti-Retroviral Drugs Sales in Volume by Application (2016-2026)
6.2 Global Anti-Retroviral Drugs Revenue by Application (2016-2026)
6.3 Global Anti-Retroviral Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Anti-Retroviral Drugs Sales by Type (2016-2026)
7.2 North America Anti-Retroviral Drugs Sales by Application (2016-2026)
7.3 North America Anti-Retroviral Drugs Market Size by Country
7.3.1 North America Anti-Retroviral Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Anti-Retroviral Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Anti-Retroviral Drugs Sales by Type (2016-2026)
8.2 Europe Anti-Retroviral Drugs Sales by Application (2016-2026)
8.3 Europe Anti-Retroviral Drugs Market Size by Country
8.3.1 Europe Anti-Retroviral Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Anti-Retroviral Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Anti-Retroviral Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Anti-Retroviral Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Anti-Retroviral Drugs Market Size by Region
9.3.1 Asia-Pacific Anti-Retroviral Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Anti-Retroviral Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Anti-Retroviral Drugs Sales by Type (2016-2026)
10.2 South America Anti-Retroviral Drugs Sales by Application (2016-2026)
10.3 South America Anti-Retroviral Drugs Market Size by Country
10.3.1 South America Anti-Retroviral Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Anti-Retroviral Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Anti-Retroviral Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Anti-Retroviral Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Anti-Retroviral Drugs Market Size by Country
11.3.1 Middle East & Africa Anti-Retroviral Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Anti-Retroviral Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Anti-Retroviral Drugs Typical Distributors
12.3 Anti-Retroviral Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Anti-Retroviral Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Anti-Retroviral Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. Cardionet Basic Information, Manufacturing Base and Competitors
Table 4. Cardionet Major Business
Table 5. Cardionet Anti-Retroviral Drugs Product and Services
Table 6. Cardionet Anti-Retroviral Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. GE Healthcare Basic Information, Manufacturing Base and Competitors
Table 8. GE Healthcare Major Business
Table 9. GE Healthcare Anti-Retroviral Drugs Product and Services
Table 10. GE Healthcare Anti-Retroviral Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Abbott Basic Information, Manufacturing Base and Competitors
Table 12. Abbott Major Business
Table 13. Abbott Anti-Retroviral Drugs Product and Services
Table 14. Abbott Anti-Retroviral Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 16. AstraZeneca Major Business
Table 17. AstraZeneca Anti-Retroviral Drugs Product and Services
Table 18. AstraZeneca Anti-Retroviral Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Bristol-Myers-Squibb Basic Information, Manufacturing Base and Competitors
Table 20. Bristol-Myers-Squibb Major Business
Table 21. Bristol-Myers-Squibb Anti-Retroviral Drugs Product and Services
Table 22. Bristol-Myers-Squibb Anti-Retroviral Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Gilead Basic Information, Manufacturing Base and Competitors
Table 24. Gilead Major Business
Table 25. Gilead Anti-Retroviral Drugs Product and Services
Table 26. Gilead Anti-Retroviral Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Cardiac Science Corp. Basic Information, Manufacturing Base and Competitors
Table 28. Cardiac Science Corp. Major Business
Table 29. Cardiac Science Corp. Anti-Retroviral Drugs Product and Services
Table 30. Cardiac Science Corp. Anti-Retroviral Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Cardiocom Basic Information, Manufacturing Base and Competitors
Table 32. Cardiocom Major Business
Table 33. Cardiocom Anti-Retroviral Drugs Product and Services
Table 34. Cardiocom Anti-Retroviral Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Biotelemetry Basic Information, Manufacturing Base and Competitors
Table 36. Biotelemetry Major Business
Table 37. Biotelemetry Anti-Retroviral Drugs Product and Services
Table 38. Biotelemetry Anti-Retroviral Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 40. GlaxoSmithKline Major Business
Table 41. GlaxoSmithKline Anti-Retroviral Drugs Product and Services
Table 42. GlaxoSmithKline Anti-Retroviral Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Roche Basic Information, Manufacturing Base and Competitors
Table 44. Roche Major Business
Table 45. Roche Anti-Retroviral Drugs Product and Services
Table 46. Roche Anti-Retroviral Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. Global Anti-Retroviral Drugs Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 48. Global Anti-Retroviral Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 49. Market Position of Manufacturers in Anti-Retroviral Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 50. Global Anti-Retroviral Drugs Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 51. Head Office and Anti-Retroviral Drugs Production Site of Key Manufacturer
Table 52. Anti-Retroviral Drugs New Entrant and Capacity Expansion Plans
Table 53. Anti-Retroviral Drugs Mergers & Acquisitions in the Past Five Years
Table 54. Global Anti-Retroviral Drugs Sales by Region (2016-2021e) & (K Pcs)
Table 55. Global Anti-Retroviral Drugs Sales by Region (2021-2026) & (K Pcs)
Table 56. Global Anti-Retroviral Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 57. Global Anti-Retroviral Drugs Revenue by Region (2021-2026) & (USD Million)
Table 58. Global Anti-Retroviral Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 59. Global Anti-Retroviral Drugs Sales by Type (2021-2026) & (K Pcs)
Table 60. Global Anti-Retroviral Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 61. Global Anti-Retroviral Drugs Revenue by Type (2021-2026) & (USD Million)
Table 62. Global Anti-Retroviral Drugs Price by Type (2016-2021e) & (USD/Pcs)
Table 63. Global Anti-Retroviral Drugs Price by Type (2021-2026) & (USD/Pcs)
Table 64. Global Anti-Retroviral Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 65. Global Anti-Retroviral Drugs Sales by Application (2021-2026) & (K Pcs)
Table 66. Global Anti-Retroviral Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 67. Global Anti-Retroviral Drugs Revenue by Application (2021-2026) & (USD Million)
Table 68. Global Anti-Retroviral Drugs Price by Application (2016-2021e) & (USD/Pcs)
Table 69. Global Anti-Retroviral Drugs Price by Application (2021-2026) & (USD/Pcs)
Table 70. North America Anti-Retroviral Drugs Sales by Country (2016-2021e) & (K Pcs)
Table 71. North America Anti-Retroviral Drugs Sales by Country (2021-2026) & (K Pcs)
Table 72. North America Anti-Retroviral Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 73. North America Anti-Retroviral Drugs Revenue by Country (2021-2026) & (USD Million)
Table 74. North America Anti-Retroviral Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 75. North America Anti-Retroviral Drugs Sales by Type (2021-2026) & (K Pcs)
Table 76. North America Anti-Retroviral Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 77. North America Anti-Retroviral Drugs Sales by Application (2021-2026) & (K Pcs)
Table 78. Europe Anti-Retroviral Drugs Sales by Country (2016-2021e) & (K Pcs)
Table 79. Europe Anti-Retroviral Drugs Sales by Country (2021-2026) & (K Pcs)
Table 80. Europe Anti-Retroviral Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 81. Europe Anti-Retroviral Drugs Revenue by Country (2021-2026) & (USD Million)
Table 82. Europe Anti-Retroviral Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 83. Europe Anti-Retroviral Drugs Sales by Type (2021-2026) & (K Pcs)
Table 84. Europe Anti-Retroviral Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 85. Europe Anti-Retroviral Drugs Sales by Application (2021-2026) & (K Pcs)
Table 86. Asia-Pacific Anti-Retroviral Drugs Sales by Region (2016-2021e) & (K Pcs)
Table 87. Asia-Pacific Anti-Retroviral Drugs Sales by Region (2021-2026) & (K Pcs)
Table 88. Asia-Pacific Anti-Retroviral Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 89. Asia-Pacific Anti-Retroviral Drugs Revenue by Region (2021-2026) & (USD Million)
Table 90. Asia-Pacific Anti-Retroviral Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 91. Asia-Pacific Anti-Retroviral Drugs Sales by Type (2021-2026) & (K Pcs)
Table 92. Asia-Pacific Anti-Retroviral Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 93. Asia-Pacific Anti-Retroviral Drugs Sales by Application (2021-2026) & (K Pcs)
Table 94. South America Anti-Retroviral Drugs Sales by Country (2016-2021e) & (K Pcs)
Table 95. South America Anti-Retroviral Drugs Sales by Country (2021-2026) & (K Pcs)
Table 96. South America Anti-Retroviral Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 97. South America Anti-Retroviral Drugs Revenue by Country (2021-2026) & (USD Million)
Table 98. South America Anti-Retroviral Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 99. South America Anti-Retroviral Drugs Sales by Type (2021-2026) & (K Pcs)
Table 100. South America Anti-Retroviral Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 101. South America Anti-Retroviral Drugs Sales by Application (2021-2026) & (K Pcs)
Table 102. Middle East & Africa Anti-Retroviral Drugs Sales by Country (2016-2021e) & (K Pcs)
Table 103. Middle East & Africa Anti-Retroviral Drugs Sales by Country (2021-2026) & (K Pcs)
Table 104. Middle East & Africa Anti-Retroviral Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 105. Middle East & Africa Anti-Retroviral Drugs Revenue by Country (2021-2026) & (USD Million)
Table 106. Middle East & Africa Anti-Retroviral Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 107. Middle East & Africa Anti-Retroviral Drugs Sales by Type (2021-2026) & (K Pcs)
Table 108. Middle East & Africa Anti-Retroviral Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 109. Middle East & Africa Anti-Retroviral Drugs Sales by Application (2021-2026) & (K Pcs)
Table 110. Direct Channel Pros & Cons
Table 111. Indirect Channel Pros & Cons
Table 112. Anti-Retroviral Drugs Typical Distributors
Table 113. Anti-Retroviral Drugs Typical Customers
List of Figures
Figure 1. Anti-Retroviral Drugs Picture
Figure 2. Global Anti-Retroviral Drugs Sales Market Share by Type in 2020
Figure 3. Protease Inhibitors
Figure 4. Non-Nucleoside Reverse Transcriptase Inhibitors
Figure 5. Integrase Inhibitors
Figure 6. Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
Figure 7. Global Anti-Retroviral Drugs Sales Market Share by Application in 2020
Figure 8. Hepatitis
Figure 9. HIV/AIDS
Figure 10. Herpes
Figure 11. Influenza
Figure 12. Others
Figure 13. Global Anti-Retroviral Drugs Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 14. Global Anti-Retroviral Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. Global Anti-Retroviral Drugs Sales (2016-2026) & (K Pcs)
Figure 16. Global Anti-Retroviral Drugs Price by Type (2016-2026) & (USD/Pcs)
Figure 17. Global Anti-Retroviral Drugs Production Capacity (2016-2026) & (K Pcs)
Figure 18. Global Anti-Retroviral Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 19. Anti-Retroviral Drugs Market Drivers
Figure 20. Anti-Retroviral Drugs Market Restraints
Figure 21. Anti-Retroviral Drugs Market Trends
Figure 22. Global Anti-Retroviral Drugs Sales Market Share by Manufacturer in 2020
Figure 23. Global Anti-Retroviral Drugs Revenue Market Share by Manufacturer in 2020
Figure 24. Anti-Retroviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. Top 3 Anti-Retroviral Drugs Manufacturer (Revenue) Market Share in 2020
Figure 26. Top 6 Anti-Retroviral Drugs Manufacturer (Revenue) Market Share in 2020
Figure 27. Global Anti-Retroviral Drugs Sales Market Share by Region (2016-2026)
Figure 28. Global Anti-Retroviral Drugs Revenue Market Share by Region (2016-2026)
Figure 29. North America Anti-Retroviral Drugs Revenue (2016-2026) & (USD Million)
Figure 30. Europe Anti-Retroviral Drugs Revenue (2016-2026) & (USD Million)
Figure 31. Asia-Pacific Anti-Retroviral Drugs Revenue (2016-2026) & (USD Million)
Figure 32. South America Anti-Retroviral Drugs Revenue (2016-2026) & (USD Million)
Figure 33. Middle East & Africa Anti-Retroviral Drugs Revenue (2016-2026) & (USD Million)
Figure 34. Global Anti-Retroviral Drugs Sales Market Share by Type (2016-2026)
Figure 35. Global Anti-Retroviral Drugs Revenue Market Share by Type (2016-2026)
Figure 36. Global Anti-Retroviral Drugs Price by Type (2016-2026) & (USD/Pcs)
Figure 37. Global Anti-Retroviral Drugs Sales Market Share by Application (2016-2026)
Figure 38. Global Anti-Retroviral Drugs Revenue Market Share by Application (2016-2026)
Figure 39. Global Anti-Retroviral Drugs Price by Application (2016-2026) & (USD/Pcs)
Figure 40. North America Anti-Retroviral Drugs Sales Market Share by Type (2016-2026)
Figure 41. North America Anti-Retroviral Drugs Sales Market Share by Application (2016-2026)
Figure 42. North America Anti-Retroviral Drugs Sales Market Share by Country (2016-2026)
Figure 43. North America Anti-Retroviral Drugs Revenue Market Share by Country (2016-2026)
Figure 44. United States Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Anti-Retroviral Drugs Sales Market Share by Type (2016-2026)
Figure 48. Europe Anti-Retroviral Drugs Sales Market Share by Application (2016-2026)
Figure 49. Europe Anti-Retroviral Drugs Sales Market Share by Country (2016-2026)
Figure 50. Europe Anti-Retroviral Drugs Revenue Market Share by Country (2016-2026)
Figure 51. Germany Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Anti-Retroviral Drugs Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Anti-Retroviral Drugs Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Anti-Retroviral Drugs Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific Anti-Retroviral Drugs Revenue Market Share by Region (2016-2026)
Figure 60. China Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Korea Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Anti-Retroviral Drugs Sales Market Share by Type (2016-2026)
Figure 67. South America Anti-Retroviral Drugs Sales Market Share by Application (2016-2026)
Figure 68. South America Anti-Retroviral Drugs Sales Market Share by Country (2016-2026)
Figure 69. South America Anti-Retroviral Drugs Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East & Africa Anti-Retroviral Drugs Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Anti-Retroviral Drugs Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa Anti-Retroviral Drugs Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Anti-Retroviral Drugs Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Egypt Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. South Africa Anti-Retroviral Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source